Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Blueberries Medical Corp. (BBM.CN)
Bogotá, CO
Headquartered in Bogotá, Colombia, Blueberries Medical Corp. operates within the medicinal cannabis industry. The company's activities encompass the entire process, from cultivating and developing to producing and supplying medical-grade cannabis and its associated products across Colombia. Their offerings notably include medicinal cannabis oil extracts and other complementary items.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -25.00% | +50.00% | +0.00% | +0.00% | -25.00% | +50.00% | +50.00% | +0.00% | -85.00% | -85.00% | -98.75% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-33.8% Q1'26: -22.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-20.7% Q1'26: +115.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-439.4% Q1'26: -32.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-441.6% Q1'26: -368.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-456.7% Q1'26: -857.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+18.5% Q1'26: +22.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.01× Q1'26: -0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
|---|---|---|---|---|
| Revenue |
66.0K
est: 5.98M (-98.9%)
|
138.7K
est: 14.53M (-99.0%)
|
235.4K
est: 26.60M (-99.1%)
|
288.3K
est: 53.16M (-99.5%)
|
| EBITDA |
-4.11M
est: -5.98M (+31.3%)
|
-4.05M
est: -14.53M (+72.1%)
|
-811.5K
est: -26.60M (+96.9%)
|
-1.22M
est: -53.16M (+97.7%)
|
| EBIT |
-4.82M
est: -5.98M (+19.4%)
|
-4.88M
est: -14.53M (+66.4%)
|
-1.11M
est: -26.60M (+95.8%)
|
-1.37M
est: -53.16M (+97.4%)
|
| Net Income |
-4.94M
est: -3.99M (-23.8%)
|
-5.15M
|
-1.47M
est: 7.98M (-118.4%)
|
-1.64M
est: 19.95M (-108.2%)
|
| SGA |
2.48M
est: 63.88M (-96.1%)
|
579.4K
est: 155.20M (-99.6%)
|
1.23M
est: 284.13M (-99.6%)
|
1.24M
est: 567.84M (-99.8%)
|
| EPS |
-0.04
est: -0.01 (-299.0%)
|
-0.03
|
-0.01
est: 0.02 (-143.5%)
|
-0.01
est: 0.05 (-115.0%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Thomas Rodriguez | Chief Financial Officer | 123.2K | male |
| Facundo Garreton | Executive Chairman & Chief Executive Officer | 122.1K | male |
| Gustavo Gutiérrez | Country Manager | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BBM.CN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
